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1. Introduction  
There are over 6000 inherited human diseases described in the McKusick Online Mendelian 
Inheritance in Man database (OMIM)(McKusick-Nathans Institute of Genetic Medicine, 
2011). They show a wide range of variability in frequency, severity, age of onset, diagnostic 
and treatment approaches. A subset of diseases induce severe metabolic disturbances in the 
newborn that can lead to irreversible damage and illnesses. For some of those, there is a 
treatment that prevents such damages as long as it is initiated early after birth. For these 
diseases, population-based newborn screening has been proposed, developed and 
implemented in many countries albeit at different rates and based on different criteria. Even 
if those diseases are rare, the burden that is prevented if treated early has been shown to be 
cost-effective as it is larger than the cost of systematic screening and treatment of the cases 
identified (Venditti et al., 2003). Different analytical methods have been deployed since the 
1960’s to detect abnormal levels of specific metabolites or hormones in the newborn’s blood 
with sufficient reliability and low cost to allow their use as screening methods (see 1.1).  
We will describe the tremendous impact that tandem mass spectrometry has had in the field 
of newborn screening for inherited diseases in the recent decade. After a brief history of 
newborn screening, we will describe the classical WHO criteria for population-based 
screening for disease, summarize impacts of tandem mass spectrometry in this field. Then, 
we will describe the laboratory workflow, the pre-examination, examination, and post-
examination aspects of MS/MS-based newborn screening, its advantages and limitations. 
Other issues will also be reviewed including sample and data management, revision of 
screening criteria and future perspectives for MS/MS in population-based screening. 
1.1 History of newborn screening 
The concept of universal population-based newborn screening (NBS) for inherited metabolic 
diseases was introduced in 1963 when a bacterial inhibition assay for phenylalanine in blood 
spots collected from newborn babies was proposed (Guthrie & Susi, 1963). This systematic 
screening identified, within the first days of life, babies with phenylketonuria (PKU). PKU, 
an autosomal recessive inborn error of metabolism is due to the deficiency of phenylalanine 
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hydroxylase (a cellular enzyme) that leads to the accumulation of phenylalanine in the 
tissues and blood of affected individuals (20-fold levels as compared to normal) (Scriver, 
2007). Phenylanaline at such levels is neurotoxic and impairs the normal development of 
brain functions after birth, amongst other problems. It affects about one newborn out of 
10,000 births in populations of Caucasian origins (1:4500 to 1:18000) (DiLella et al., 1986). If 
left undetected and untreated, PKU leads to irreversible mental retardation which can be 
prevented with a low phenylalanine diet initiated rapidly at birth. Newborn screening of 
PKU has become the classical example of a good screening practice and is accepted as a 
standard care in all developed countries (Lehotay et al., 2011). 
In the following decade, only a few other diseases have been added to NBS, especially 
congenital hypothyroidism (CH). CH has an estimated incidence of 1:200 to 1:4000 (Rastogi 
& LaFranchi, 2010). Initially thyroxine (a lipophilic small molecule hormone) was measured 
as the screening entry test but this was later replaced with measurements of TSH (a peptide 
hormone) by immunoassay methods. It is estimated that approximately 25% of all newborns 
worldwide are tested at least for hypothyroidism (Wilcken, 2007). Depending on the 
incidence of other specific detectable and treatable metabolic diseases some countries have 
added a few more diseases (e.g. galactosemia, cystic fibrosis (CF), congenital adrenal 
hyperplasia (CAH) and, tyrosinemia) were added in certain countries (Pitt, 2010). 
In 1990, it was proposed that MS/MS could be used to test for multiple analytes 
simultaneously in dried blood spots from newborn screening programmes (Millington et al., 
1990). However, at that time, a significant technical challenge constituted in analyzing 
hundreds of samples per day injected individually by means of a probe that needed to be 
cleaned before the next sample (Pollitt, 2006). This laborious process was relieved by the 
application of electrospray ionization to biomolecules and availability of commercially 
developed robust and easily cleaned sources of ions, as well as data systems to manage the 
resultant output (Pollitt, 2006; Johnson et al., 1996; Rashed et al., 1995). The following years 
revealed that MS/MS, which was already used in the clinical laboratory for quantitation of 
metabolites and drugs, could also be used as a primary method for NBS of inborn errors of 
metabolism. This technology was suitable because most of the molecules to measure were 
small metabolites, it allowed simultaneous analysis of a wide variety of different analytes, it 
was compatible with high-throughput (2-3 min per sample) and low reagent costs at the 
same time as being sensitive and specific (Chace, 2009). It has been estimated that, when 
using the American College of Medical Genetics (ACMG) panel of markers (see below), one 
affected newborn will be identified by MS/MS for every 3000 births (Rinaldo et al., 2006). 
 
Year Milestone Reference 
1963 PKU Screening (bacterial growth inhibition) (Guthrie & Susi, 1963) 
1968 WHO Screening Criteria (Wilson & Junger, 1968) 
1973 Addition of Congenital Hypothyroidism Screening (Dussault & Laberge, 1973) 
1975 Tyrosinemia Screening in specific population (Québec) (Laberge et al., 1975) 
1990 Proposal to use MS/MS for newborn screening (Millington et al., 1990) 
1993 Proof of concept for NBS by MS/MS  (Chace et al., 1993) 
1995 Electrospray Ionization applied to NBS (Rashed et al., 1995) 
2006 ACMG proposed panel for NBS by MS/MS  (ACMG Newborn Screening 
Expert Group, 2006) 
2008 Revised newborn screening criteria (Andermann et al., 2008) 
Table 1. Some of the major milestones for newborn screening. 
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1.2 Criteria for population screening 
Population screening traditionally has aimed only at diseases that fulfill a set of widely 
accepted criteria for population-based screening proposed in 1968 by Wilson and Junger, as 
commissioned by the World Health Organization (WHO)(Wilson & Junger, 1968; Table 2).  
 
Principal Wilson and Jungner Criteria for 
Screening (WHO, 1968) 
 Knowledge of disorder and its natural history if 
screening did not occur; 
 Availability of, access to and knowledge of how 
presymptomatic interventions change natural 
history of disorder, prevented irreversible harms, 
improved outcomes and reduced morbidity and 
mortality; 
 Screening test is simple with very high sensitivity 
and specificity and cost benefit ratio; 
 Resources exist for follow up of individuals with 
positive screening for confirmatory testing, 
introduction and monitoring of treatment and for 
counseling of family in the case of genetic 
diseases; 
 These Principles are acceptable to the consumer, 
the “target population”.  
In short 
 Knowledge of disorder 
 Presymptomatic intervention 
improving outcomes 
 Simple and low cost test with 
excellent performances 
 Resources available for follow-up 
of positive individuals 
 Acceptability of program 
Table 2. Principal Wilson and Jungner criteria for screening. 
These criteria are applicable to systematic or population-based screening (i.e. of 
asymptomatic persons) for any type of disease and have been considered best practice since 
their publication in 1968. They thus apply not only to inherited diseases but to screening for 
any disease. They have been used by public health authorities to evaluate candidate tests or 
programs for population based screening. Since only few tests and diseases have historically 
met the criteria, population-based screening programs, including newborn screening, have 
historically targeted very few diseases. The first criteria asks that the natural history of the 
disorder be very well known, especially if there is no screening offered. This includes the 
proportion of untreated individuals that will develop severe and irreversible organ damages 
before they develop symptoms and seek a medical consultation. That is, because 
population–based screening (pre-symptomatic by definition) will usually not be cost-
effective if the progressing disease causes symptoms before producing severe consequences. 
The second criteria refers to the presence of evidence that, if the disease is detected before it 
generates symptoms, there is an intervention (or treatment) to propose that will improve the 
outcomes. If there is no effective intervention with proven beneficial effects that can be 
offered to prevent the development of the disease after a positive screening test, then there 
may be no point in performing this test. The third criteria asks for a screening test that is 
simple, costs little and has good clinical specificity and sensitivity. In a screening context, 
sensitivity is very important as the very purpose of a screening program is to detect most if 
not all individuals that will develop the disease, thus the false negative rate (the proportion 
of disease cases that will test negative) must be as low as possible. However, if the screening 
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test has poor specificity and too many false positive results (normal individuals that will test 
positive), then too many positive results will need to be confirmed by further testing which 
will not be cost-effective at all. Indeed, one of the major cost drivers for a screening program 
is the rate of false positive screening results. This is easily understood, as for example, if a 
disease has an incidence of 1 in 10000 newborns, and the false positive rate is 5%, then for 
each true positive case, the screening test will produce 500 false positives that will need to 
be reclassified as negative after a confirmation test. The fourth criteria refers to the 
availability of health care and financial resources to provide the true positive cases with 
appropriate follow-up and treatment, as well as the necessary genetic counseling if the 
disease screened is an inherited condition. Finally, any population-based screening program 
also needs to be acceptable to the population to whom it will be offered. This is also an 
important aspect as social acceptability of a program can significantly affect participation 
rate and undermine the very objectives of a screening program. 
With the advent of multiplex screening methods such as MS/MS, allowing simultaneous 
detection of several tens of analytes in a single run, these criteria have been challenged and 
it has been proposed to revise them (Section 4) (Andermann et al., 2008). Countries and 
health care jurisdictions are still attempting to find a balance between the technological 
drive to provide all the data available when analyzing a newborn sample by MS/MS and 
the necessity to fulfill rational criteria before screening entire populations for diseases. 
1.3 Impact of MS/MS spectrometry on newborn screening  
Tandem mass spectrometry, by its very nature, has the potential to detect and quantify 
many molecules of similar physicochemical properties at the same time, provided the 
appropriate sample preparation steps and technical parameters are used (see below). This 
constitutes a dramatic change as compared to the classical methods used for newborn 
screening before the advent of MS/MS in this field. This is the major reason for the 
accepted fact that MS/MS has profoundly changed the paradigm of newborn screening 
(Chace et al., 2003), and possibly of screening per se. The wide variety of newborn 
screening panels that are currently in operation in various countries (Table 3) exemplifies 
the choices that decision makers in each health jurisdiction have to make especially with 
respect to which diseases to screen for (or not). Not all countries have published the 
results of their newborn screening programmes but it is interesting to see that the 
incidence of infants with inherited metabolic disorders identified by MS/MS screening is 
significant, ranging from 1:1800 to 1:6200 newborn. Also, according to the information 
publicly available at the present time, the number of metabolic disorders screened by 
MS/MS in newborns ranges from 0 to over 40. Many jurisdictions have not implemented 
MS/MS yet, while others are still refining their panel of diseases that are included in the 
screening assays. The reasons for this wide variety of practices include accessibility to 
funding for an expensive clinical MS/MS screening infrastructure, but also the absence of 
uniformly accepted practice guidelines with respect to what diseases should be included 
in a newborn screening programme. While the American College of Medical Geneticists 
(ACMG Newborn Screening Expert Group, 2006) recommended a large core panel of 29 
inherited metabolic diseases, the UK National screening committee (UK National 
Screening Committee, 2011) recommends screening for only five diseases (Watson et al., 
2006). It is worth mentioning here that, while MS/MS is a powerful diagnostic and 
measurement technology, some of the analytes to be measured in NBS are not easily 
amenable to MS/MS (e.g. hemoglobins and thyroid hormones).  
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Country/ 
Province/ 
State 
Total number of 
diseases 
screened for 
Number of 
diseases  
screened by 
MS/MS 
Overall prevalence of 
infants with inherited 
metabolic disorders 
identified by MS/MS 
Reference 
Canada 
(Québec) 
4 1 nd (Laflamme et al., 2005) 
Canada 
(Ontario) 
25 20 nd 
(Children's Hospital of 
Eastern Ontario, 2011) 
Canada 
(Saskashewan) 
32 nd nd (Lehotay et al., 2011) 
USA (NewYork) 47 37 nd 
(Wadsworth Center, 
2011) 
USA 
(Minnesota) 
30 29 1:1816 (Rinaldo et al., 2006) 
USA (California) 50 44 nd 
(California Department 
of Public Health, 2011) 
UK (recomm.) 5 nd nd 
(UK National Screening 
Committee, 2011) 
Australia 
(Victoria) 
25 23 
 
nd 
(Victorian Government 
Department of Health, 
2011) 
Spain nd 10 nd (Bodamer et al., 2007) 
Switzerland 2 0 nd (Bodamer et al., 2007) 
Austria nd 25 1:2855 (Kasper et al., 2010) 
Taiwan nd 21 1:6219 (Niu et al., 2010) 
Table 3. Comparison of some existing NBS programs worldwide (nd=no data). 
2. Laboratory considerations 
2.1 Laboratory workflow and management 
A typical newborn screening laboratory receives between 100 to 1000 dried newborn blood 
spot samples (See 2.2.1) per working day for analysis. The general target for the turn around 
time to perform the analytical screening procedure and producing the laboratory report is 
two to four working days, because for some diseases treatment must be started rapidly to 
prevent irreversible damage to the infant (See 2.4.2). Confirmatory analyses are needed 
rapidly after a positive screening test result. Thus, although the same tests are repeated, 
there are several levels of complexity and management issues to address due to the sheer 
volume and time pressure facing the NBS laboratory. With such constraints, the NBS 
laboratory needs to prevent any type of service interruption and have back-up solutions to 
cover all possible aspects of the process with appropriate redundancy. Also, the clinical 
newborn screening laboratory should implement a Quality Management System for all 
laboratory processes as proposed in best practice guidelines such as ISO15189 (International 
Organization for Standardization, 2003) and NCCLS GP26 (NCCLS, 2004). This must be in 
place to ensure real-time measurement of appropriate indicators of the system’s integrity in 
all phases of the pre-examination, examination and post-examination processes.  
Apart from the laboratory processes themselves (see below), the NBS laboratory will usually 
be at the center of a complex set of activities surrounding the NBS programme. It is not in 
the scope of this chapter to describe those aspects in details but here are some examples. 
There are processes that precede the sampling procedure and for which the NBS laboratory 
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may be responsible, such as managing and maintaining the stocks of virgin sampling cards 
and forms in the various hospitals and nurseries participating in the program. Systematic 
follow-up processes should be in place to ensure that no sample is left unattended and to 
rapidly refer positive cases to a health care facility that will initiate treatment very rapidly. 
Laboratory managers may also be in direct contact with the public agency commissioning 
the NBS programme, but also with health care facilities and professionals upstream and 
downstream of the sampling-to-reporting process itself. There is wide variability in the 
organization of the different NBS programmes worldwide. 
 
 
Fig. 1. NBS Laboratory Flowchart. 
With respect to the NBS laboratory activities per se (see Figure 1) the three classical pre-
examination (or preanalytical), examination and post-examination (or postanalytical) phases 
include the various stages and processes involved in sample and request forms flows 
between their arrival in the laboratory and the reporting of results. Data management is 
described later in this chapter and the details of each phase through which samples and 
forms go through are also discussed in the following sections. 
2.2 Pre-examination considerations 
Pre-examination conditions are crucial in order to ensure the performance of specimen 
analysis. The time of the sampling, the delay between the sampling and reception in the 
laboratory, the baby’s condition (e.g. prematurity, parenteral nutrition, recent transfusion) 
can influence screening results and thus the life of the baby. Due to these limitations, it is 
important to note that the screening test result is not diagnostic and requires confirmation 
with an independent sample and method (Pitt, 2010). It has been estimated that there is a 
measurement error of ±30% due to the fact of using blood dots on filter paper as sample in 
part because it is done in many locations and by many people (Lehotay et al., 2011). Of note, 
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with metabolic diseases, several-fold increases of metabolite levels are usually expected. In 
addition to specimen collection, storage and transport are also potential sources of errors.  
2.2.1 Dried blood spots as samples and their management 
Specimen collection 
Collection of blood onto an absorbent paper card (dried blood spots: DBS) represents the 
most common type of NBS sample. On a filter paper, a few drops from a heel prick are dried 
in air for a few hours before being sent to the NBS laboratory. This filter paper is attached 
with a card that includes specific spaces for writing the family names of the father, the 
mother, their address and phone number, the date and hour of the newborn’s birth, the date 
and hour of sampling, and the birth hospital (Figure 2). Each NBS card has a unique a 
number or bar code. In the province of Québec, a multiple identification of the newborn is 
done by 1) names of the parents, 2) the sampling card number which is unique for the each 
newborn and provides information of the location of the birth and 3) the date of birth. A 
complete information card is mandatory for the specimen to be valid and accepted by the 
NBS laboratory. Otherwise, a new and appropriately identified sample is needed. 
 
  
Fig. 2. Example of a newborn screening blood sampling card and its attached filter paper. 
The heel puncture must be done on the planar surface of the foot in the safest area (medial 
to a line drawn posteriorly from the middle of the great toe to the heel or lateral to a line 
drawn from between the 4th and 5th toe to the heel.) according to the H3A6 CLSI guidelines. 
No foreign substance around the filter paper must contaminate the sample. Blood must 
completely fill all printed circles and is applied evenly on one side of the filter (but must 
also fill completely the minimal sample circle on the other side of the paper), free of layering 
and clots. It must be correctly dried (4 hours of air drying at room temperature). Laboratory 
analysis of the sample depends on an assumed amount of blood in the filter paper. Criteria 
for adequate sampling are summarized by Wadsworth Center (2011) and Kayton (2007). 
Timing of collection is important because some metabolite’s levels vary with the infant’s age 
(Wilcken & Wiley, 2008). Sampling within 24-72 hours of age is common practice. If it occurs 
too early (<24 hours of age), a new specimen may be required. Prematurity, birth weight, 
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parenteral nutrition, transfusion, type of feeding, neonatal jaundice and drugs affect 
metabolite levels (Rolinski et al., 2000) and may influence laboratory results. Such facts 
should be documented on the NBS card to help interpretation of results (Pitt, 2010).  
Transport 
Delays in transport can cause degradation of some markers and result in false negative 
results. Samples should be sent within 24 hours after collection. Batching causes delays in 
reception and processing of samples and may have serious consequences on the life of an 
affected newborn (Kayton, 2007). Upon arrival of samples to the NBS laboratory, verification 
of sampling card information and validation of specimen adequacy is performed. A 
laboratory identification number is generated for each sample card.  
2.2.2 Automation of pre-analytical steps 
Given the large volume of samples to analyze in a timely and reproducible way, automation 
of some pre-analytical steps has been implemented in many NBS laboratories. A micro-
volume pipetting station and punchers help to shorten turn around time in the NBS 
laboratory. The puncher (basic, semi-automatic or automatic) is a convenient tool with 
minimal user intervention. It punches the sampling cards where a blood spot is located and 
drops the punch into a microplate. Punchers can read bar codes and some have a light guide 
to help the technician to optimally position the sample card and verify that the disk falls into 
the well. More sophisticated punchers are fully automated and accept 300 samples at a time. 
The micro-volume pipettor can pipet 96 well plates. It is a compact unit, with high precision 
(1µl /min dispensing, CV 5%) control of dispense rate and calibration values.  
2.3 Examination considerations   
In the following section, we discuss the particular aspects of tandem mass spectrometry as 
applied to the analysis of dried blood spot samples for newborn screening (NBS).  
2.3.1 Types of sample preparation procedures 
In the context of NBS, two types of pre-analytical sample treatments are in use: with or 
without derivatisation. After reception, verification and labeling of NBS sampling cards, a 
punch (generally 3.2 mm in diameter) is deposited in a 96 well plate and the position of each 
specific sample is noted (usually electronically by reading a bar code on the sampling card). 
Extraction of the analytes from sample card punches is usually performed with a solution 
comprised mainly of methanol, but including isotope-labeled internal standards for the 
main amino acids and acylcarnitines that will be measured. Quantification of the 
metabolites of interest will use these internal standards as a reference. The derivatisation 
method is more frequently used because of its greater sensitivity. This method will produce 
butyl derivatives. New methods without derivatisation are becoming more popular with the 
help of new generations of MS/MS instruments with increased sensitivity. This method 
simplifies the sample preparation steps by removing the butylation of metabolites with a 
toxic and corrosive reagent. This reduces significantly sample preparation time. For the 
majority of quantitative results for acylcarnitines and amino acids, the two methods differ 
by less than 15% (De Jesus et al., 2010). However, larger differences are observed for 
dicarboxylic acylcarnitine compounds, especially for short chains such as C5DC (glutaryl-
carnitine). Raw counts for the non-derivatised method are much smaller as compared to the 
derivatisation method, although quantitative results are similar. C5DC is a major marker for 
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glutaric aciduria type I. It is thus important to pay particular attention to this marker. The 
newer and more sensitive generation of MS/MS instruments may compensate for these 
lower values. Use of a non-derivatised method can induce a lack of differentiation of 
isobaric acylcarnitines, as well as increase false-positive rates for certain disorders, and cut-
offs should be adjusted accordingly (De Jesus et al., 2010). 
2.3.2 Technical configurations of MS/MS for newborn screening 
A typical configuration for tandem mass spectrometry for a newborn screening laboratory 
includes four components (Figure 3). The first one is an HPLC-type of pump ensuring the 
flow of a mobile phase, but with no liquid chromatography step. The second component 
injects samples into the mobile phase before it reaches the MS/MS. Pipetting of each sample 
is performed by an auto-sampler for 96-well plates and hundreds of samples per day.  
 
 
Fig. 3. Schematic configuration for tandem mass spectrometry for newborn screening. 
The third component comprises the two mass spectrometers that scan the analytes in each 
sample, identify and quantify the various signals from metabolites of interest and transfer 
the raw information to the fourth component, a computer system, which performs the 
formal quantification of each metabolite and integrate the information into a useful data set. 
 
 
Fig. 4. Schematic representation of the flow of ions in a tandem mass spectrometer. Adapted 
from Waters Micromass Quattro Premier XE Mass Spectrometer Operator’s Guide. 
The tandem mass spectrometer itself comprises five major elements (Figure 4) : 1- the source 
where samples in liquid phase are injected, ionized and introduced into the first quadrupole 
MS; 2- the first quadrupole MS, where a first selection of ions by their m/z ratio is 
performed (many ions with similar m/z ratios may be selected); 3- the beam is directed into 
a collision cell where ions collide with Argon molecules which break ions having entered 
the cell (mother ions) into smaller ions (daughter ions) specific to each mother ion; 4- the 
second quadrupole MS receives these fragments and filters the daughter ions of interest 
(green arrow) to identify the presence of molecules of interest, with internal standards to 
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support quantification; 5- an ion detector counts each ion that passes through the second MS 
at each specific m/z ratio and transfers the information to the computer system for analysis. 
Many types of sources of ions are used in mass spectrometry, depending on the application. 
An important aspect of tandem mass spectrometry applied to NBS is electrospray ionization 
(ESI). ESI is a method of obtaining ions without destroying molecules in the sample. It was 
developed by John Bennett Fenn who received the Nobel prize of chemistry for this in 2002. 
Before the development of ESI, it was very difficult to directly inject a liquid phase into a 
MS, as the interface between a liquid chromatograph and the MS was not easily performed; 
only gas chromatography was easily interfaced with MS. ESI (Figure 5) operates by sending 
a liquid sample through an electrically charged capillary tube. A continuous flow of 
nitrogen along the capillary creates a spray of charged liquid at the end of the capillary. 
Charged droplets are formed and their evaporation shrinks their size until they burst due to 
electric repulsion, which leaves individual molecules that are charged and ready to be 
injected into the MS, after being accelerated according to their charge. 
 
 
Fig. 5. Schematic representation of electrospray ionization. The liquid sample flows through 
a charged capillary (left), which produces positively charged droplets attracted by a 
negatively charged electrode that accelerates charged micro droplets into the MS/MS. 
Adapted from Balogh & Stacey (1991). 
Finally, ions are selected and analyzed according to their mass to charge ratio (m/z) by the 
quadrupoles in tandem. Each quadrupole consists in four parallel rods defining the edges of 
a rectangular cuboid. Each rod has an opposite charge to its neighbor rod and the same as its 
opposite rod. The value of the m/z ratio of ions selected by the quadrupole is determined by 
a radio frequency superimposed with a continuous voltage applied to the quadrupole’s 
electrodes (rods). For a specific radio frequency, there is a cut-off where ions of a specific 
m/z and larger will pass through. Thus the radio frequency acts as a filter of minimal m/z 
ratio. Inversely, the combination of continuous potential and the radiofrequency act as a 
filter of maximal m/z ratio. Thus addition of the appropriate voltage to a radio frequency 
selects a specific m/z ratio under which ions will not pass through the quadrupole. 
2.3.3 Performing the analysis 
In the context of newborn screening, the objective of the analysis is to identify selected 
inherited metabolic disorders of clinical significance.  
As for any laboratory analysis, prior to offering a clinical laboratory test, the laboratory must 
validate (in the case of home-made reagents) or verify (in the case of commercial kits) the 
analytical method it will be implementing. This will usually include correlation with an 
www.intechopen.com
 
Newborn Screening by Tandem Mass Spectrometry: Impacts, Implications and Perspectives 
 
761 
established (or other validated) method, intra-run and inter-run reproducibility studies, 
carryover studies, linearity, recovery, precision, trueness, etc. These studies are needed to 
ensure the robustness and performance of the analytical method and the overall analytical 
process in the specific context of a physical laboratory facility. Cut-offs for detection of 
metabolites of interest should also be established. Accuracy of the assay is important near 
the cut-off value for each analyte. During the set-up phase for MS/MS assays in the 
laboratory, up to 2500 to 4000 samples may be needed to establish the appropriate cut-offs 
for metabolites levels that will be considered as positive upon screening results. Cut-offs are 
also compared with other screening laboratories and can be adjusted with the collection and 
analysis of larger number of samples over time. The difficulty is to establish a cutoff value 
for each metabolite in order to detect diseases and, at the same time, to minimize the 
occurrence of false negative and false positive screening results. 
 
 
Fig. 6. Typical output for a newborn sample analysed by Multiple  Reaction Monitoring 
(MRM ) in MSMS. In this MSMS spectrum, targeted ion masses of interest, corresponding to 
markers for several inherited metabolic diseases, are  divided in three parts : 1 :MRM of 24 
aminoacids; 2 : MRM of 21 acyl-carnitines from C0 to C8:1; 3 : MRM of 23 acylcarnitines 
from C10 to C18OH;.  x axis = m/z ; y axis = % intensity which relates to each metabolite 
concentration. Concentrations are compared with cut-offs for each corresponding analyte, 
defining an abnormal or normal metabolic profile for this newborn. 
Also, prior to launching the test offer, the clinical laboratory must implement a quality 
assessment program for the analytes that will be measured. A typical output for a newborn 
sample is shown in Figure 6. Each run is checked by inspection of TIC (total ion current 
chromatogram) of each sample, internal standard and all quality control (QC) samples. In 
the laboratory, quality controls (QC) (low and high levels) are run with each batch of 
newborn samples and contribute to determining the adequacy of the run. Low level controls 
reflect the normal endogenous metabolites and high level controls reflect concentrations 
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near the cut-off value or an abnormal state for each analyte. For each plate a minimum of 
one low QC and one high QC must be present. These QCs are “internal quality controls” 
given that their expected value is known to the lab performing the analysis. It is advised that 
other controls (such as external controls (of unknown value) or known cases) would also be 
present in the plate (Lehotay et al., 2011). With proficiency testing (external QC), there are 
several different dimensions of the screening processes that are examined. The laboratory 
processes - as if they were real samples - materials of unknown value (to the testing 
laboratories) provided by a proficiency testing program that then compares the results from 
several different participating laboratories. The complexity in developing the QC materials 
for MS/MS in NBS is high. Moreover, participation and comparison of results within 
collaborative projects such as Region 4S project (Region 4 Genetics Collaborative, 2007), 
and/or to a quality control program such as the CDC program where performance criteria 
are collected from several laboratories is relevant and useful to test the performance of the 
NBS laboratory and essential to insure short and long term quality of results (Chace et al., 
1999; Adam et al., 2000; Hannon et al., 1997).  
2.3.4 Advantages and limitations of MS/MS  
MS/MS technology offers a new approach to NBS by having the ability to screen rapidly for 30 
or more metabolic disorders in a single analysis from one small blood sample using a simple 
protocol (Chace et al., 2003). Indeed, in one run, more than 40 analytes can be quantified. This 
capacity decreases the NBS laboratory turn around time because many metabolites can be 
measured in parallel as opposed to sequentially. It is also potentially clinically efficient because 
screening of metabolic disorders asks for more than one marker to be measured to define the 
disease. With MS/MS, there is the possibility to produce a rather complete metabolic profile 
for a patient in a single run. However this great advantage comes with the limitation that some 
“disorders” detected by MS/MS can be benign or mild. An ethical question is thus raised with 
respect to how the laboratory, and the physicians, will deal with this information that is of 
undetermined clinical value (Lehotay et al., 2011). As compared with other methods used in 
the past, MS/MS showed a high analytical performance for detecting diseases of high 
frequency, notably MCAD deficiency and PKU. However, the technology’s analytical 
performance is not identical for all analytes measured. (for instance succinyl acetone for the 
screening of tyrosinemia Type I). Thus, some important diseases of the newborn such as 
tyrosinemia type I have higher false positive rates by MS/MS than by more conventional 
methods (Chace et al., 2003). This led to the development of a number of second tier tests 
requiring a separate testing protocol with a rapid turn around time (Magera et al., 2006; Sander 
et al., 2006). Another limitation of MS/MS is raised by the diagnostic dilemma when one or 
several markers are the same for more than one disease. For instance C5OH is a marker of 
severe disease such as holocarboxylase synthase deficiency as well as a marker for a generally 
benign condition, namely 3 methylcrotonylCoA Carboxylase deficiency (Dantas et al., 2005; 
Koeberl et al., 2003). Despite these limitations, implementation of tandem mass spectrometry 
has generated a significant evolution in newborn screening programs, often referred-to as a 
paradigm shift.  
2.3.5 Metabolites measured 
Several metabolites are measured by MS/MS in a newborn screening laboratory.  Generally, 
they arise from protein metabolism (amino acids), fatty acid and organic acid metabolism  
(acylcarnitines), or from endocrine metabolism (hormones or specific metabolites). To 
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determine those metabolites to be integrated to a newborn screening MS/MS profile, it is 
important to have an excellent understanding of human metabolism. An enzymatic defect 
along a metabolic pathway can result in accumulation of the substrate and insufficient levels 
of the product of this enzyme. The accumulation of substrate - or its by-products -, or the 
decreased concentration of a normal product - or by-product - can be identified in the 
MS/MS spectrum and quantified. One challenge in newborn screening testing is that some 
metabolites are markers for several diseases, that is, they are not specific to a single 
metabolic disorder. To circumvent the issue of disease specificity, ratios of some markers are 
usually computed (Region 4 Genetics Collaborative, 2007). Extensive lists of markers that 
can be analyzed by MS/MS for newborn screening profiles are already published (ACMG, 
2006; De Jesus et al., 2010; Lehotay et al., 2011). Some diseases that need to be screened for 
are not yet readily amenable to MS/MS and thus most NBS laboratories also run other types 
of assays for these conditions. 
Because of pre-examination and examination concerns, screening assays are not equivalent 
to diagnostic assays. In order to allow for high throughput and multiple metabolite 
detection, some compromises have to be made on the assay’s analytical performances. For 
[false] positive samples, these are in part compensated by more specific 2nd-tier assays (see 
2.4.1). However, negative screening results will not be retested and thus false negative 
screening results have to be minimized in the context of a screening program, even if 
somewhat more false positive results will be generated at the initial screening step.  
2.4 Post-examination considerations 
After the screening examination phase is completed, the laboratory needs to determine 
which samples need confirmation and also to produce a laboratory report. As the disorders 
screened in NBS are rare, the majority of results are normal, but test performance will 
strongly influence delivery of ambiguous or false positive results, with its implications in 
terms of repeat testing, investigation, and parental stress. The expansion of NBS to a 
significantly increased number of disorders by MS/MS technology has only amplified and 
complexified the management of NBS programs during and following sample analysis.  
2.4.1 Interpretation of screening results 
If the expansion of NBS by MS/MS is a breakthrough in the field, it also represents a major 
challenge for NBS laboratory personnel who are faced with a significant increase in data 
generated, as was mentioned in previous sections (see 2.3.3 and 2.3.4).   
Performance characteristics of the NBS procedures will depend upon chosen tests cut-offs. If 
the threshold level for a disorder is too high, a proportion of newborns with a disorder will 
be missed, while a threshold that is too low will generate many additional positive screen in 
infants without the disease. The increased number of conditions tested, each of them being 
rare, led to the implementation of 2nd tier confirmatory tests that are more complex, time-
consuming and unsuitable for high throughput mass screening but with performance 
characteristics of increased sensitivity and specificity. The main aim is to diminish the 
number of false positive screens. The problem is more acute for primary tests that lack 
specificity and generate a high rate of false positives (for specific examples, see section 2.4.4). 
The false positive rate is the proportion of positive tests in newborns that eventually turn 
out to be normal after follow up evaluation, while the positive predictive value of a test, a 
function of the sensitivity, the specificity and the prevalence of the condition, is the 
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probability that the infant tested positive has the disease. With about four millions births 
annually in the USA and each infant screened for about 30 conditions, assuming a specificity 
of 99.9% of the primary test for each disorder to be screened, this amounts to about 50,000 
false positive results per annum in the USA only.  
One must emphasize that the introduction of MS/MS in NBS, a very sensitive and specific 
technology, is not in itself responsible for the increased number of false positive screens, the 
phenomenon is rather a consequence of the increased number of extremely rare disorders 
that are included in the NBS panels. This may be unavoidable if NBS programs aim to 
screen infants for very rare inborn metabolic disorders. As an example, despite a sensitivity 
of about 100% and a specificity of 99.96%, after confirmatory testing, only eight (8) 
newborns were true positives out of the 1249 who initially tested positive for maple syrup 
urine disease (MSUD) in the USA in 2007 (3,364,612 were tested for MSUD overall) (Schulze 
et al., 2003). Undoubtedly, NBS protocols must include the diagnostic confirmation of a 
positive screen before any clinical intervention is instituted, otherwise a large number of 
infants would be given inappropriate treatment. Targets of adequate analytical and post-
analytical performance in the era of NBS expansion by MS/MS multiplex testing have been 
proposed: false positive rate < 0.3%, positive predictive value > 20% (Rinaldo et al., 2006). 
Interestingly, novel NBS algorithms are being proposed, and 2nd tier testing, characterized 
by high sensitivity and specificity may also be used to identify rapidly newborns that would 
have otherwise been missed (i.e. false negatives) by reducing a primary test cut-off followed 
by 2nd testing on the initial blood spot for the increased number of abnormal results from the 
primary test, enhancing the performance of NBS (Turgeon et al., 2010). 
 
Example of conditions Primary markers 
Example of informative 
Ratios 
Some Other 
Conditions with same 
markers
Argininosuccinic 
acidemia citrullin Citrullin/arginin Citrullinemia  
Citrullinemia types 1 
and 2 citrullin Citrullin/arginin Citrullinemia  
Maple syrup disease Valine, leucine- isoleucine
Valine/phenylalanine
Leu-isoleucine/alanine ketosis 
Phenylketonuria phenylalanine Phenylalanine/tyrosine Diet, prematurity 
Type 1 Tyrosinemia Succinylacetone (the best), tyrosine Tyrosine/citrulline 
Prematurity, types 2-3 
tyrosinemias 
Types 2 and 3 
tyrosinemia tyrosine Tyrosine/citrulline 
Prematurity, type1- 
tyrosinemias 
Medium chain acyl-
coA dehydrogenase 
deficiency 
C6, C8, C10:1, C10 C8/C2; C8/C10 Glutaric type 2 
Short chain acyl-coA 
dehydrogenase 
deficiency 
C4 C4/C2; C4/C3, C4/C8 Glutaric type 2 
Glutaric acidemia 
type1 C5DC 
C5DC/C5OH, C5DC/C8, 
C5DC/C16 Glutaric type 2 
Propionic acidemia C3 C3/C2,C3/C16 Cobalamine deficiency (C, D)
Methylmalonic 
acidemia (Cobalamin 
deficiency) 
C3 C3/C2,C3/C16, C3/Methionine 
Propionic acidemia, 
Cobalamin deficiency 
A, B
Table 5. Examples of markers for some conditions, adapted from Lehotay et al. (2011). 
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Thus, not all abnormal results indicate the presence of an inborn error of metabolism and 
consequently they must be confirmed by a diagnostic or confirmatory procedure (see 2.4.3). 
Of note, interpretation of results must distinguish between an ongoing pathologic process 
and changes in metabolite concentrations due to the maturation process of organ systems. 
Discrimination between a frankly abnormal result and an undetermined result usually rely 
on the observed pattern of biochemical abnormality. Most inborn errors of metabolism have 
specific primary analytes associated with the condition (Table 5).  
The presence of secondary markers or analyte ratios can increase the specificity of the 
screening procedure for the disorder associated with a primary analyte. Other concerns also 
arise in the presence of a positive screen or ambiguous result. Indeed, some conditions, such 
as prematurity (delivery < 37 weeks gestation), low birth weight (< 2500 g), some 
medications, total parenteral nutrition and newborn sickness unrelated to an inborn error of 
metabolism may cause up to 40% of false positive results (Lehotay et al., 2011). In such 
circumstances, repeat sampling is usually requested. Recently, the CLSI has issued 
guidelines and recommendations for repeat testing in these specific circumstances (Miller et 
al., 2009). Reports of abnormal results must thus include a qualitative interpretation by a 
NBS professional well versed in metabolic patterns associated with disorders, but also with 
factors that may mimic the presence of a screened condition. 
2.4.2 Reporting of results 
Despite recommendations by the American Academy of Pediatrics (AAP) newborn 
screening task force (Mandl et al., 2002), there exists a wide variety of practices between 
NBS programs regarding notification of results. While most programs will notify primary 
health care providers of results from all newborns, whether results are normal or positive, a 
few states and one Canadian province will issue results only if abnormal. All NBS programs 
in the USA report abnormal results and monitor follow up activities, but the reporting of 
abnormal results by NBS programs includes a wide diversity of approaches such as 
telephone call, letter, certified letter, secured web-based electronic letter and fax. All USA 
states send a report to the infant’s pediatrician, and most report to the hospital of birth, the 
parents and a geneticist (Kayton, 2007). Considering the importance of follow-up of 
abnormal results for potentially life threatening conditions, the vast majority of states will 
follow up until it is confirmed that the screened infant with an abnormal result has a follow 
up appointment, and about half will track until a diagnosis is made and treatment is 
initiated.  Only a few states however will continue to follow up periodically (Kayton, 2007).  
Timely notification of parents of newborns screened positive for disorders with potentially 
disastrous evolution is critical. Notification of results depends on age at blood sample 
collection (which varies between NBS programs), dispatch, transfer to the NBS laboratory 
and processing. The UK Newborn Screening Program Center has recommended targets for 
reception and processing of samples and notification of results using PKU as the prototype 
disorder (NHS Newborn Bloodspot Screening Programme, 2008). Overall, 99.5% of samples 
should be received by 16 days of life, samples should be processed within 4 working days, 
ideally within 2 working days, and 100% of screened positives should be notified before the 
infant is 18 days old, with treatment initiation by 21 days of life, if confirmed. Ideally, 80% of 
screened positives should be notified by 12 days of life, with initiation of therapy before 14 
days of life of the infant confirmed positive. As discussed previously, the impact of an 
expanded NBS panel by MS/MS are significant for both the NBS personnel and health care 
providers: much more interventions and communications to pediatricians are made by the 
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former, including the reporting of an increased number of false positive and ambiguous 
results, while the latter are faced with the investigation of infants for disorders for which 
little is known about the natural history or may be benign conditions. In 2009, the National 
Academy of Clinical Biochemistry (NACB) issued guidelines for optimal follow up testing 
for positive newborn screens using MS/MS (Dietzen et al., 2009). 
2.4.3 Confirmation testing in a NBS program 
Classically, a positive NBS result needs a repeat analysis in duplicate from the initial blood 
spot before repeat sampling is requested. If the result is confirmed positive with the 
repeated screening test, the need to perform additional testing depends on the disorders for 
which the infant is presumably positive and the availability of a second tier test for that 
disorder. Second tier tests are reflex tests performed on the same dried blood sample as the 
primary screening test. The relevance to perform a 2nd tier test is justified by the possibility 
of false positive screens or the presence of an ambiguous result in the presence of poor 
specificity of the primary screening test for a specific disorder. As mentioned earlier, the 
expansion of NBS for multiple rare disorders causes a significant increase in the number of 
false positive results, which increases the burden on laboratory personnel, health care 
providers, not to mention parental stress. 2nd tier tests allow to confirm results with 
increased specificity on the initial blood spot. A typical example is NBS screening of 
congenital adrenal hyperplasia (CAH) using 17-OH progesterone by fluoro-immunoassay. 
The method lacks specificity, is affected in the presence of prematurity and neonate 
illnesses, and cross reacts with structurally similar steroids, notably 17-OH pregnenolone. 
The second tier tests measures 17-OH pregnenolone by LC-MS/MS (Etter et al., 2006), but 
also cortisol and androstenedione. The ratio of (17 OH-P + androstenedione)/cortisol, 
increases discrimination since 17-OH-P and androstenedione are increased while cortisol is 
decreased in CAH (Schwarz et al., 2009; Lacey et al., 2004; Minutti et al., 2004). Another 
example is the presence of elevated propionylcarnitine (C3), which may suggest the 
presence of propionic acidemia, but is a non specific marker, also present in methylmalonic 
acidemia, a disorder of cobalamin metabolism. Further analysis using original blood spots 
for 3-OH-propionic and methylmalonic acids performed as 2nd tier tests allow to rule in or to 
rule out propionyl and methylmalonyl acidemia. These 2nd tier tests increase the specificity 
of the screening procedure, with less than 5% of positive C3 being confirmed as true 
positives (la Marca et al., 2007). Follow up testing for plasma acylcarnitines, along with 
other markers, have been developed to determine if the presumptive screened positive are 
truly positive and if so, for which condition. A number of other inborn errors of metabolism 
need a 2nd tier test to increase positive predictive value. 
2.4.4 Short term follow-up of confirmed positive cases 
In the presence of a sample that screened positive for a disorder, the NBS laboratory must 
report the results for rapid clinical evaluation, diagnosis and appropriate management of 
the newborn. Actions needed for complete and secure transmission of the information are 
not only dependent upon the NBS laboratory, but must be coordinated by a structured 
program. Indeed, a number of services will be needed, such as metabolic, enzymatic and/or 
molecular diagnostic laboratories, but also specialized health care providers such as 
geneticists, endocrinologists and metabolic dieticians. Newborns screened positive may be 
referred to either the primary health care providers or directly to tertiary specialized 
services, depending to the structure of health care services.  
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Because of the rapid increase in the number of rare disorders screened with the expansion of 
NBS by MS/MS, primary health care providers are increasingly faced with the referral of 
infants with a rare disorder. Results may be presented as analytes measured and/or 
conditions screened, and should include a clear interpretation, especially in the case of 
screened positive. Importantly, abnormal results of a screened positive do not mean that the 
infant has the disease, as additional investigation may be needed before a final diagnosis is 
reached. Classically, treatment is not initiated before the diagnosis is confirmed and parents 
have received appropriate counseling. With the increased number of conditions screened, it 
is thus even more imperative that the reporting of screened positive infant be presented in 
adequate and comprehensible format to the health care provider. To help physicians 
structure their approach in the provision of care for these newborn, the American College of 
Medical Genetics (ACMG) has developed a tool, called the ACT Sheet and confirmatory 
diagnosis, which provides information for each condition involved in NBS. The tool 
includes 1) a 1-page ACTion (ACT) sheet that describes short term actions and 
communication with the family and determining the appropriate follow up steps for the 
infant that has screened positive, and 2) a 1-page algorithm with an overview of the basic 
steps involved in determining the final diagnosis in the infant (ACMG, 2011). The ACT sheet 
and confirmatory algorithm exist for various disorders (endocrine, haematological, genetic 
and metabolic), and each ACT sheet includes links to informational resources.   
There is no doubt that expansion of NBS by MS/MS to a large number of disorders poses 
organisational challenges. As many rare conditions are screened for, NBS programs and 
health care professional must deal with the uncertainty about the natural history of these 
rare conditions. The laboratory is central to the whole NBS process: it must develop a test 
menu that includes specific 2nd tier testing protocols in order to confirm the biochemical 
abnormality and identify the underlying metabolic condition (see Table 6 for examples).  
 
 
Disorder Example of follow-up marker(s) 
 Example of follow-up 
method(s) 
Phenylcetonuria phenylalanine, tyrosine in plasma 
ion exchange 
chromatography (IEC) 
 urine organic acids GCMS 
MSUD valine, leucine, isoleucine IEC 
 alloisoleucine in plasma  
 urine organic acids GCMS 
Argininosuccinic acidemia argininosuccinate, citrulline IEC 
 urine organic acid GCMS 
Medium chain acyl CoA   C6, C8, C10 acylcarnitine in plasma LCMS/MS 
dehydrogenase deficiency 
(MCAD) 
urinary organic acid GCMS 
glutaric aciduria type1 plasma C5DC acyl carnitine   LCMS/MS 
 urine organic acid GCMS 
glutaric aciduria type2 
plasma C5DC, C5, C5OH, C6, C8, C10-
C16 acyl-carnitines 
LCMS/MS 
 urine organic acid GCMS 
Additional tests with cells and enzymatic assays can confirm the diagnosis  
 
Table 6. Examples of follow-up testing for positive cases in newborn screening program 
(adapted from Dietzen et al., 2009). 
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Highly structured NBS programs will favour the increase in knowledge about these rare 
conditions, and will ultimately improve provision of care for these infants, communication 
between parents and health care professional and will reduce parental anxiety related to 
uncertainty (Deluca et al., 2011). Implementation of electronic health information exchange 
(HIE) is an opportunity for quality improvement of NBS. With harmonization of standards, 
coding and terminology and implementation of decision-making and support tools, access 
to HIE by health care professionals should result in improved effectiveness of short and 
long term management of infants with an inborn error of metabolism (Downs et al., 2010). 
2.4.5 Conservation of dried blood spots 
NBS laboratories receive dried blood spots (DBS) specimens from virtually all newborns 
from their territory. NBS specimens represent an unbiased source of blood that can generate 
new population-based knowledge, including potential improved children’s health, but also 
new understanding on the background of both child and adult disease. In addition, NBS is 
probably the only program reaching the entire population, representing, for instance, about 
4 millions births/year in the USA. To ensure proper security, confidentiality, privacy and 
public confidence in NBS practices, each jurisdiction must regulate NBS practices regarding 
retention and storage of DBS. Owing to the implementation of molecular techniques using 
DBS, there is a growing interest in the use of these unique samples for purposes other than 
NBS, such as genomic research. Stored DBS specimens have also been used to establish the 
presence of congenital cytomegalovirus infection (Barbi et al., 2006; de Vries et al., 2009) and 
for forensic purposes (Couzin-Frankel, 2009). 
Currently, storage and secondary use of DBS is controversial and two distinct approaches 
are in use, a short-term storage approach (i.e. < 2-3 years) and a long-term approach (more 
than 5-10 years). While the first approach allows the standard use of DBS for quality 
insurance and program evaluation, treatment efficacy, test refinement and result 
verification, the latter one further allows the use of DBS for research purposes, that is for 
purposes other than those for which they were originally collected. Parents from Minnesota 
and Texas have charged their respective health departments because DBS specimens had 
been stored without parents’ knowledge or consent. This is not surprising, in the absence of 
national guidelines and of diverse practices regarding retention and use of specimen in the 
USA (Lewis et al., 2011) and Canada (Avard et al., 2006). In Texas, as part of the settlement 
more than 5 millions DBS specimens dating back to 2002 were destroyed (Grody & Howell, 
2010; Rollins, 2011). Recently, the Secretary’s Advisory Committee on Heritable Disorders in 
Newborns Children (SACHDNC) published a briefing paper which reviewed the issues 
facing the state NBS programs related to retention and use of residual DBS specimens and 
proposed a foundation for developing national guidelines (Secretary’s Advisory Committee 
on Heritable Disorders in Newborns and Children, 2010). This included recommendations 
for the implementation of a policy on access, disposition, protection of privacy and 
confidentiality of residual DBS specimens. Biobanking residual DBS for secondary use was 
also addressed by the President’s Council on Bioethics (President’s Council on Bioethics, 
2008). Noteworthy, in 1993 the Denmark government implemented a national newborn 
screening biobank addressing most of these issues (Norgaard-Pedersen & Simonsen, 1999). 
The Organization for Economic Co-operation and Development (OECD) with the 
International Society for Biological and Environmental Repositories jointly developed best 
practice guidelines useful to implement such policies in NBS (Baust, 2008; OECD, 2007). 
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Use of stored DBS specimens requires stability and integrity of samples. Stability will 
depend on the analyte to be measured. Non-DNA material such as amino acids left at room 
temperature may degrade within a few months (Therrell et al., 1996), but may be stable for 
years at -200C. Long-term storage at ambient temperature results in significant degradation 
of acylcarnitines, which are hydrolysed into free carnitine and corresponding fatty acids, 
and aminoacids (Strnadova et al., 2007). The velocity of the decay is logarithmic, depends on 
chain length of acylcarnitine (Fingerhut et al., 2009), and appropriate correction for storage 
should be applied. Acylcarnitines are stable at -180C for at least one year (Fingerhut et al., 
2009). On the other hand, DNA quality from stored DBS specimens at room temperature 
allowed extraction and successful amplification for at least 25 years (Searles Nielsen et al., 
2008). Quantitative RNA stability was also shown from stored residual NBS specimens for 
20 years at 40C in controlled relative humidity maintained at 30% (Gauffin et al., 2009). 
Specimen-to-specimen contamination should be prevented. 
3. Data management  
Given that each newborn sample is unique and needs to be analyzed with reliability and in 
a systematic way, data management is an important component of the newborn screening 
laboratory infrastructure. Typically, the data management system, or laboratory information 
system (LIS) is expected to manage sample and patient information, interact with the 
computers onboard both the sample preparation instruments, the analytical 
instrumentation, manage the various analytical and interpretation algorithms, as well as the 
production of reports and their transmission to the appropriate health care professional(s). 
Ideally, the LIS should be able to compute laboratory production statistics, gather and 
analyze quality control procedures as well as contribute, at least partly, to the laboratory’s 
Quality System indicators. Data storage is usually regulated within each health jurisdiction 
with respect to its duration, access by various stakeholders and usage. Laboratory data can 
also be used to evaluate the NBS laboratory’s performance. Typically, monitoring of the rate 
of positive samples (which should remain stable over time), the ratios of various analytical 
signals within samples, the false positive rate, signal-to-noise ratios can be very useful for 
laboratory professionals and managers to detect either failures in a laboratory process, or 
sometimes actual deterioration of the quality of a specific production step or equipment that 
merit some attention to prevent more serious problems. In the context of laboratories that 
process all newborn samples from a specific geographic region, particular attention must be 
placed on preventing a production shutdown which would be very detrimental in the 
context of diseases that could remain undetected for a longer period of time than acceptable.  
4. Revised criteria for population screening 
The low reagent cost of MS/MS and its capacity to detect several tens of metabolites in a 
single run have challenged the paradigm of population screening criteria. As discussed 
above, different countries have introduced MS/MS technology and expanded the number of 
disorders in their panel at very different rates after applying different policies and 
approaches. Two such extremes are the UK, which screen only for a few disorders and the 
USA where most states now screen for 30 disorders and more. Indeed, if the UK health 
authorities approved MS/MS in principle, apart from PKU and MCADD, no further 
expansion is envisioned before more data are produced on evidence of benefits of NBS for 
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other disorders (Pandor et al., 2004). At the other end of the spectrum, most states in the 
USA now comply to the proposed American College of Medical Genetics (ACMG) core 
panel of 29 disorders to be screened as primary targets, and an additional 25 disorders (so 
called secondary targets) that should be identified and reported through full MS/MS 
profiling (Watson et al., 2006). Many countries, such as Germany, Switzerland and 
Australia, but also some states in the USA and provinces in Canada, have performed their 
own evaluation process resulting in expansion to a number of disorders in between both 
extremes. Clearly, the original screening principles established by Wilson and Junger in 1968 
(Wilson & Junger, 1968) - discussed in section 1.2 - have not been applied strictly to NBS. 
This may be a consequence of the qualitative terms of the Wilson and Junger principles, 
which make them difficult to use as decision tools. However, the difficulty also arises from 
the nature of NBS for metabolic diseases which are rare disorders with unclear natural 
history and benefits of preventive measures/treatment due to desperately lacking data. 
Consequently, as more disorders with very low prevalence and heterogeneous clinical 
characteristics are added to the NBS panel, it becomes difficult to establish the balance 
between potential benefits and harms, as well as to evaluate cost-effectiveness. Interestingly, 
a recent report showed that parents of children affected with very rare disorders are much 
in favor of NBS, even for untreatable disorders, mainly because NBS may eliminate a 
painful diagnostic odyssey (Plass et al., 2010). On the other hand, the recent report from the 
US Chair on Bioethics unequivocally rejected the technological imperative as a argument for 
NBS (President’s Council on Bioethics, 2008). It is beyond the scope of this chapter to detail 
the ethical stakes of NBS expansion, but as pointed out by Botkin et al (2006), when neither 
benefits nor harms are well characterized, a more cautious approach may be warranted.  
There is no consensus on whether Wilson and Junger screening principles might or might 
not be applicable for NBS and the ACMG panel shows a number of flaws (Moyer et al., 
2008). Randomized controlled trials may be warranted in NBS, and there is a need to 
develop a rigorous process to assess available evidence and develop decision tools. 
Recently, a proposal for reviewed Wilson and Junger screening principles was published in 
the WHO-bulletin (Andermann et al., 2008). In addition the UK National Screening 
Committee (NSC) further expanded the 10 Wilson and Junger screening principles into 19 
more specific criteria and 87 items of information under 35 general headings (UK National 
Screening Committee, 2011). These attempts at better defining screening criteria and their 
evaluation may help public health authorities to better determine which disorders should be 
implemented into universal public health NBS programs as innovations and new 
knowledge is reported. Also, cost-effectiveness studies, when available, will inform decision 
makers about screening options and the impact of various parameters within specific health 
jurisdictions and population contexts (Venditti et al., 2003, Pandor et al., 2004). 
5. Perspectives for tandem mass spectrometry in population screening  
Tandem mass spectrometry has become a standard method in routine clinical laboratories. 
The field of newborn screening for inherited metabolic diseases has shown to be a natural fit 
for this technology that is both sensitive, precise and allows multiplex analyses of several 
tens of analytes from very small samples. Since year 2000, tens of thousands infants and 
their families have already benefited from the early identification and treatment of their 
inherited metabolic disease that has been allowed by this technology. Industry has also 
rapidly adapted and now proposes turnkey solutions for large panels of relevant (and 
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perhaps less relevant) NBS metabolites (Lehotay et al., 2011). New methods are proposed on 
a regular basis and, in the near future, it would not be surprising to witness the availability 
of MS/MS approaches for the more complex molecules such as the peptides measured in 
congenital hypothyroidism and hemoglobinopathies. Progresses at automation of many 
steps of MS/MS in the clinical laboratory (Vogeser & Kirchhoff, 2011), as well as 
miniaturization of instruments (e.g. by the use of nanosprays and microfluidics) also open 
new avenues for further improvement of the efficacy of these techniques. 
The existence of unresolved questions is highlighted by the great variety in the size of 
testing panels offered in different jurisdictions, as well as significant discrepancies between 
existing guidelines for NBS programs with respect to the diseases to be screened. Future 
applications of this powerful technology will likely include the detection and measurement 
of peptides and complex molecules with potential applications in NBS. Although other 
analytical methods will continue to be needed either to screen for specific molecules, or for 
confirmatory studies of samples positive on screening, tandem mass spectrometry in the 
field of newborn screening is already a pillar technology and is promised to a great future. 
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